Iovance Biotherapeutics Stock News

SAN CARLOS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on November 18, 2021 (the Date of Grant), the Company approved the grant of inducement stock options covering an aggregate of 168,575 shares of Iovances common stock to seven new non-executive employees.

Iovance Biotherapeutics, Inc. (IOVA) with the stream of 0.05% also noticed, India Motus GI Holdings, Inc. (MOTS) encountered a rapid change of 0.50% in the last hour of Tuesdays trading The post Take This As A Wake-Up Call: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), Motus GI Holdings, Inc. (NASDAQ:MOTS) appeared first on Stocks Equity .

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced data for lifileucel in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients with advanced cancers. Data were p

The stock price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) increased by over 4% pre-market today. This is why it happened.

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in Cohort 3B of the basket study IOV-COM

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

Iovance Biotherapeutics' (IOVA) third-quarter loss is wider than expected. The company is progressing well in terms of development of pipeline candidates.

Iovance Biotherapeutics' (IOVA) CEO Fred Vogt on Q3 2021 Results - Earnings Call Transcript

Iovance Biotherapeutics (IOVA) has been struggling lately, but the selling pressure may be coming to an end soon.

The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Iovance Biotherapeutics (IOVA). While the effectiveness of this highly sought-after metric is question

SAN CARLOS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients with Advanced Cancers

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab  in Immune Checkpoint Inhibitor-Naïve Patients with Advanced Cancers

Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders

First Patient Infused with TIL Cell Therapy Manufactured at iCTC